Literature DB >> 27693090

Evaluation of lung tumor response to therapy: Current and emerging techniques.

E Coche1.   

Abstract

Lung tumor response to therapy may be evaluated in most instances by morphological criteria such as RECIST 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI). However, those criteria are limited because they are based on tumoral dimensional changes and do not take into account other morphologic criteria such as density evaluation, functional or metabolic changes that may occur following conventional or targeted chemotherapy. New techniques such as dual-energy CT, PET-CT, MRI including diffusion-weighted MRI has to be considered into the new technical armamentarium for tumor response evaluation. Integration of all informations provided by the different imaging modalities has to be integrated and represents probably the future goal of tumor response evaluation. The aim of the present paper is to review the current and emerging imaging criteria used to evaluate the response of therapy in the field of lung cancer.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Computed tomography; Lung tumor; PET-CT; Perfusion; RECIST

Mesh:

Year:  2016        PMID: 27693090     DOI: 10.1016/j.diii.2016.09.001

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  5 in total

1.  Combination of Circulating Tumour DNA and 18F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study.

Authors:  Ondrej Fiala; Jan Baxa; Martin Svaton; Lucie Benesova; Renata Ptackova; Tereza Halkova; Marek Minarik; Petr Hosek; Marcela Buresova; Jindrich Finek; Jiri Ferda; Milos Pesek
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

Authors:  Shigeki Nanjo; Wei Wu; Niki Karachaliou; Collin M Blakely; Junji Suzuki; Yu-Ting Chou; Siraj M Ali; D Lucas Kerr; Victor R Olivas; Jonathan Shue; Julia Rotow; Manasi K Mayekar; Franziska Haderk; Nilanjana Chatterjee; Anatoly Urisman; Jia Chi Yeo; Anders J Skanderup; Aaron C Tan; Wai Leong Tam; Oscar Arrieta; Kazuyoshi Hosomichi; Akihiro Nishiyama; Seiji Yano; Yuriy Kirichok; Daniel Sw Tan; Rafael Rosell; Ross A Okimoto; Trever G Bivona
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

3.  Development of Improved Version of Quality of Life Assessment Instrument for Lung Cancer Patients Based on Traditional Chinese Medicine (QLASTCM-Lu).

Authors:  Ting-Ting Wang; Li-Yun He; Ming Zhang; Shao-Mo Wang; Ai-Guang Zhao; Lei Chu; Li-Yuan Zhang; Sheng-Fu You; Jie You
Journal:  Chin J Integr Med       Date:  2018-11-27       Impact factor: 1.978

Review 4.  [Quantitative Imaging Assessment of Tumor Response to Chemoradiation 
in Lung Cancer].

Authors:  Yuxin Jiao; Yanping Ren; Xiangpeng Zheng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-06-20

5.  Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  So Hyeon Bak; Hyunjin Park; Insuk Sohn; Seung Hak Lee; Myung-Ju Ahn; Ho Yun Lee
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.